Aim: To determine if neoadjuvant chemoradiotherapy (nCRT) affects p53 and SOX2 expression in esophageal adenocarcinoma (EAC). Materials & methods: Comparison of p53 and SOX2 expression in 100 paired pre- and post-nCRT EAC samples. Results: Aberrant p53 was largely concordant (75/83, 90%), while 13/18 (72%) pre-nCRT samples with wild-type (WT) p53 staining, showed aberrant staining in paired post-nCRT samples. Similarly, 31/45 (69%) with previous WT SOX2 showed SOX2 loss in paired post-nCRT samples, whereas aberrant SOX2 loss was concordant in 50/55 (91%) cases. The prognostic values of both markers regarding survival differ before and after nCRT. Conclusion: Aberrant expression of p53 and SOX2 staining in EAC tissue is unaffected by nCRT. Conversely, the WT-staining pattern frequently changed to aberrant expression.

Additional Metadata
Keywords biomarkers, esophageal adenocarcinoma, esophageal neoplasms, neoadjuvant therapy SOX2 protein, tumor suppressor protein p53
Persistent URL,
Journal Biomarkers in Medicine
Rights no subscription
Suzuki, L, Nieboer, D, van Lanschot, J.J. (Jan Jb), Spaander, M.C.W, Looijenga, L.H.J, & Biermann, K. (2020). Effect of neoadjuvant chemoradiotherapy on p53 and SOX2 protein expression in esophageal adenocarcinoma. Biomarkers in Medicine, 14(9), 785–793. doi:10.2217/bmm-2020-0135